The recent 2018 guidelines from the AHA and American Stroke Association provided a class III recommendation in administering IV tissue plasminogen activator (tPA) to patients on factor Xa inhibitors or direct thrombin inhibitors unless coagulation laboratory parameters are within reasonable limits or the respective NOACs have been on hold for at least 48 hours [53]. This evidence concerns the gene PLAT and stroke disorder.